Clinical Trials Logo

CHAPLE clinical trials

View clinical trials related to CHAPLE.

Filter by:
  • None
  • Page 1

NCT ID: NCT04209634 Completed - Clinical trials for CD55-deficient Protein-losing Enteropathy

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

Start date: January 27, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of the study is to determine the effect of pozelimab on active CD55-deficient protein-losing enteropathy (PLE; CHAPLE). The secondary objectives of the study are: - To evaluate the safety and tolerability of pozelimab in patients with CD55-deficient PLE disease - To evaluate the effect of pozelimab on CD55-deficient PLE (both patients with active disease at baseline and those with inactive disease on eculizumab, switching to pozelimab) - To determine the effects of pozelimab on albumin and other serum proteins (total protein, immunoglobulins) - To determine the effects of pozelimab on ascites - To determine the effects of pozelimab on stool consistency - To determine the effect of pozelimab on health-related quality of life - To determine the effect of pozelimab on lab abnormalities observed in CD55-deficient PLE such as hypertriglyceridemia, thrombocytosis, and hypovitaminosis B12 - To describe the effects of pozelimab on the sparing of concomitant medications and reduction in hospitalization days - To determine the effects of pozelimab on growth - To characterize the concentration of pozelimab in patients with CD55-deficient PLE - To assess the incidence of treatment-emergent ADA for pozelimab in patients with CD55-deficient PLE disease